Login Register Cart 0
Generic placeholder image

Current Alzheimer Research

Editor-in-Chief

ISSN (Print): 1567-2050
ISSN (Online): 1875-5828

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe Translate in Chinese
Mini-Review Article

Complex Processes Underlying the Dynamic Changes of D-serine Levels in AD Brains

Author(s): Xiance Ni and Hisashi Mori*

Volume 19, Issue 7, 2022

Published on: 31 May, 2022

Page: [485 - 493] Pages: 9

DOI: 10.2174/1567205019666220328123048

Price: $65

Abstract

Background: Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by extracellular β-amyloid (Aβ) plaques and cognitive impairments. D-Serine, produced by the enzyme serine racemase (SR) in the brain, functions as an endogenous co-agonist at the glycine-binding site of N-methyl-D-aspartate receptor (NMDAR), has been implicated in the pathophysiological progression of AD.

Objectives: Evidence regarding the understanding of the role and dynamic modulation of D-serine during AD progression remains controversial. This literature review aims to offer novel research directions for studying the functions and metabolisms of D-serine in AD brains.

Methods: We searched PubMed, using D-serine/SR and AD as keywords. Studies related to NMDAR dysfunction, neuronal excitotoxicity, D-serine dynamic changes and inflammatory response were included.

Results: This review primarily discusses: (i) Aβ oligomers’ role in NMDAR dysregulation, and the subsequent synaptic dysfunction and neuronal damage in AD, (ii) D-serine’s role in NMDAR-elicited excitotoxicity, and (iii) the involvement of D-serine and SR in AD-related inflammatory pathological progression.

Conclusion: We also presented supposed metabolism and dynamic changes of D-serine during AD progression and hypothesized that: (i) the possible modulation of D-serine levels or SR expression as an effective method of alleviating neurotoxicity during AD pathophysiological progression, and (ii) the dynamic changes of D-serine levels in AD brains possibly resulting from complex processes.

Keywords: Alzheimer’s disease, D-serine, serine racemase, NMDAR, cognition, synaptic transmission, neurodegeneration.

Next »
[1]
Dingledine R, Borges K, Bowie D, Traynelis SF. The glutamate receptor ion channels. Pharmacol Rev 1999; 51(1): 7-61.
[PMID: 10049997]
[2]
Mori H. Overview of the NMDA receptorsThe NMDA receptors. Humana Press 2017; Vol. 30: pp. p1-p18.
[http://dx.doi.org/10.1007/978-3-319-49795-2_1]
[3]
Hashimoto A, Nishikawa T, Oka T, Takahashi K. Endogenous D-serine in rat brain: N-methyl-D-aspartate receptor-related distribution and aging. J Neurochem 1993; 60(2): 783-6.
[http://dx.doi.org/10.1111/j.1471-4159.1993.tb03219.x] [PMID: 8419554]
[4]
Matsui T, Sekiguchi M, Hashimoto A, Tomita U, Nishikawa T, Wada K. Functional comparison of D-serine and glycine in rodents: The effect on cloned NMDA receptors and the extracellular concentration. J Neurochem 1995; 65(1): 454-8.
[http://dx.doi.org/10.1046/j.1471-4159.1995.65010454.x] [PMID: 7790891]
[5]
Hashimoto A, Oka T, Nishikawa T. Extracellular concentration of endogenous free D-serine in the rat brain as revealed by in vivo microdialysis. Neuroscience 1995; 66(3): 635-43.
[http://dx.doi.org/10.1016/0306-4522(94)00597-X] [PMID: 7644027]
[6]
Berger AJ, Dieudonné S, Ascher P. Glycine uptake governs glycine site occupancy at NMDA receptors of excitatory synapses. J Neurophysiol 1998; 80(6): 3336-40.
[http://dx.doi.org/10.1152/jn.1998.80.6.3336] [PMID: 9862928]
[7]
Yang Y, Ge W, Chen Y, et al. Contribution of astrocytes to hippocampal long-term potentiation through release of D-serine. Proc Natl Acad Sci USA 2003; 100(25): 15194-9.
[http://dx.doi.org/10.1073/pnas.2431073100] [PMID: 14638938]
[8]
Mothet JP, Rouaud E, Sinet PM, et al. A critical role for the glial-derived neuromodulator D-serine in the age-related deficits of cellular mechanisms of learning and memory. Aging Cell 2006; 5(3): 267-74.
[http://dx.doi.org/10.1111/j.1474-9726.2006.00216.x] [PMID: 16842499]
[9]
Mothet JP, Parent AT, Wolosker H, et al. D-serine is an endogenous ligand for the glycine site of the N-methyl-D-aspartate receptor. Proc Natl Acad Sci USA 2000; 97(9): 4926-31.
[http://dx.doi.org/10.1073/pnas.97.9.4926] [PMID: 10781100]
[10]
Maekawa M, Watanabe M, Yamaguchi S, Konno R, Hori Y. Spatial learning and long-term potentiation of mutant mice lacking D-amino-acid oxidase. Neurosci Res 2005; 53(1): 34-8.
[http://dx.doi.org/10.1016/j.neures.2005.05.008] [PMID: 15996778]
[11]
Shleper M, Kartvelishvily E, Wolosker H. D-serine is the dominant endogenous coagonist for NMDA receptor neurotoxicity in organotypic hippocampal slices. J Neurosci 2005; 25(41): 9413-7.
[http://dx.doi.org/10.1523/JNEUROSCI.3190-05.2005] [PMID: 16221850]
[12]
Wolosker H, Blackshaw S, Snyder SH. Serine racemase: A glial enzyme synthesizing D-serine to regulate glutamate-N-methyl-D-aspartate neurotransmission. Proc Natl Acad Sci USA 1999; 96(23): 13409-14.
[http://dx.doi.org/10.1073/pnas.96.23.13409] [PMID: 10557334]
[13]
Miya K, Inoue R, Takata Y, et al. Serine racemase is predominantly localized in neurons in mouse brain. J Comp Neurol 2008; 510(6): 641-54.
[http://dx.doi.org/10.1002/cne.21822] [PMID: 18698599]
[14]
Lin H, Jacobi AA, Anderson SA, Lynch DR. D-Serine and serine racemase are associated with PSD-95 and glutamatergic synapse stability. Front Cell Neurosci 2016; 10: 34.
[http://dx.doi.org/10.3389/fncel.2016.00034] [PMID: 26941605]
[15]
Wolosker H, Balu DT, Coyle JT. The rise and fall of the D-serine-mediated gliotransmission hypothesis. Trends Neurosci 2016; 39(11): 712-21.
[http://dx.doi.org/10.1016/j.tins.2016.09.007] [PMID: 27742076]
[16]
Kartvelishvily E, Shleper M, Balan L, Dumin E, Wolosker H. Neuron-derived D-serine release provides a novel means to activate N-methyl-D-aspartate receptors. J Biol Chem 2006; 281(20): 14151-62.
[http://dx.doi.org/10.1074/jbc.M512927200] [PMID: 16551623]
[17]
Wang LZ, Zhu XZ. Serine racemase expression in mouse cerebral cortex after permanent focal cerebral ischemia. Acta Pharmacol Sin 2004; 25(4): 436-41.
[PMID: 15066209]
[18]
Sasabe J, Chiba T, Yamada M, et al. D-serine is a key determinant of glutamate toxicity in amyotrophic lateral sclerosis. EMBO J 2007; 26(18): 4149-59.
[http://dx.doi.org/10.1038/sj.emboj.7601840] [PMID: 17762863]
[19]
Perez EJ, Tapanes SA, Loris ZB, et al. Enhanced astrocytic d-serine underlies synaptic damage after traumatic brain injury. J Clin Invest 2017; 127(8): 3114-25.
[http://dx.doi.org/10.1172/JCI92300] [PMID: 28714867]
[20]
Sasabe J, Miyoshi Y, Suzuki M, et al. D-amino acid oxidase controls motoneuron degeneration through D-serine. Proc Natl Acad Sci USA 2012; 109(2): 627-32.
[http://dx.doi.org/10.1073/pnas.1114639109] [PMID: 22203986]
[21]
Balu DT, Pantazopoulos H, Huang CCY, et al. Neurotoxic astrocytes express the D-serine synthesizing enzyme, serine racemase, in Alzheimer’s disease. Neurobiol Dis 2019; 130: 104511.
[http://dx.doi.org/10.1016/j.nbd.2019.104511] [PMID: 31212068]
[22]
Long JM, Holtzman DM. Alzheimer disease: An update on pathobiology and treatment strategies. Cell 2019; 179(2): 312-39.
[http://dx.doi.org/10.1016/j.cell.2019.09.001] [PMID: 31564456]
[23]
Tarawneh R, Holtzman DM. The clinical problem of symptomatic Alzheimer disease and mild cognitive impairment. Cold Spring Harb Perspect Med 2012; 2(5): a006148.
[http://dx.doi.org/10.1101/cshperspect.a006148] [PMID: 22553492]
[24]
Jack CR Jr, Bennett DA, Blennow K, et al. Contributors. NIA-AA Research framework: Toward a biological definition of Alzheimer’s disease. Alzheimers Dement 2018; 14(4): 535-62.
[http://dx.doi.org/10.1016/j.jalz.2018.02.018] [PMID: 29653606]
[25]
McKhann GM. Changing concepts of Alzheimer disease. JAMA 2011; 305(23): 2458-9.
[http://dx.doi.org/10.1001/jama.2011.810] [PMID: 21673298]
[26]
Bateman RJ, Xiong C, Benzinger TL, et al. Dominantly inherited alzheimer network. clinical and biomarker changes in dominantly inherited Alzheimer’s disease. N Engl J Med 2012; 367(9): 795-804.
[http://dx.doi.org/10.1056/NEJMoa1202753] [PMID: 22784036]
[27]
Fagan AM, Xiong C, Jasielec MS, et al. Dominantly inherited Alzheimer network. longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer’s disease. Sci Transl Med 2014; 6(226): 226ra30.
[http://dx.doi.org/10.1126/scitranslmed.3007901] [PMID: 24598588]
[28]
Price JL, Ko AI, Wade MJ, Tsou SK, McKeel DW, Morris JC. Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease. Arch Neurol 2001; 58(9): 1395-402.
[http://dx.doi.org/10.1001/archneur.58.9.1395] [PMID: 11559310]
[29]
de Wilde MC, Overk CR, Sijben JW, Masliah E. Meta-analysis of synaptic pathology in Alzheimer’s disease reveals selective molecular vesicular machinery vulnerability. Alzheimers Dement 2016; 12(6): 633-44.
[http://dx.doi.org/10.1016/j.jalz.2015.12.005] [PMID: 26776762]
[30]
Andrade-Moraes CH, Oliveira-Pinto AV, Castro-Fonseca E, et al. Cell number changes in Alzheimer’s disease relate to dementia, not to plaques and tangles. Brain 2013; 136(Pt 12): 3738-52.
[http://dx.doi.org/10.1093/brain/awt273] [PMID: 24136825]
[31]
Mota SI, Ferreira IL, Rego AC. Dysfunctional synapse in Alzheimer's disease - a focus on NMDA receptors. Neuropharmacology 2014; 76(Pt A): 16-26.
[32]
Parameshwaran K, Dhanasekaran M, Suppiramaniam V. Amyloid beta peptides and glutamatergic synaptic dysregulation. Exp Neurol 2008; 210(1): 7-13.
[http://dx.doi.org/10.1016/j.expneurol.2007.10.008] [PMID: 18053990]
[33]
Selkoe DJ. Normal and abnormal biology of the beta-amyloid precursor protein. Annu Rev Neurosci 1994; 17(1): 489-517.
[http://dx.doi.org/10.1146/annurev.ne.17.030194.002421] [PMID: 8210185]
[34]
Chen GF, Xu TH, Yan Y, et al. Amyloid beta: Structure, biology and structure-based therapeutic development. Acta Pharmacol Sin 2017; 38(9): 1205-35.
[http://dx.doi.org/10.1038/aps.2017.28] [PMID: 28713158]
[35]
Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer’s disease. Trends Pharmacol Sci 1991; 12(10): 383-8.
[http://dx.doi.org/10.1016/0165-6147(91)90609-V] [PMID: 1763432]
[36]
Frautschy SA, Baird A, Cole GM. Effects of injected Alzheimer beta-amyloid cores in rat brain. Proc Natl Acad Sci USA 1991; 88(19): 8362-6.
[http://dx.doi.org/10.1073/pnas.88.19.8362] [PMID: 1924295]
[37]
Kowall NW, Beal MF, Busciglio J, Duffy LK, Yankner BA. An in vivo model for the neurodegenerative effects of beta amyloid and protection by substance P. Proc Natl Acad Sci USA 1991; 88(16): 7247-51.
[http://dx.doi.org/10.1073/pnas.88.16.7247] [PMID: 1714596]
[38]
Näslund J, Haroutunian V, Mohs R, et al. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA 2000; 283(12): 1571-7.
[http://dx.doi.org/10.1001/jama.283.12.1571] [PMID: 10735393]
[39]
McLean CA, Cherny RA, Fraser FW, et al. Soluble pool of Abeta amyloid as a determinant of severity of neurodegeneration in Alzheimer’s disease. Ann Neurol 1999; 46(6): 860-6.
[http://dx.doi.org/10.1002/1531-8249(199912)46:6<860:AID-ANA8>3.0.CO;2-M] [PMID: 10589538]
[40]
Mucke L, Masliah E, Yu GQ, et al. High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: Synaptotoxicity without plaque formation. J Neurosci 2000; 20(11): 4050-8.
[http://dx.doi.org/10.1523/JNEUROSCI.20-11-04050.2000] [PMID: 10818140]
[41]
Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL. Natural oligomers of the Alzheimer amyloid-β protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci 2007; 27(11): 2866-75.
[http://dx.doi.org/10.1523/JNEUROSCI.4970-06.2007] [PMID: 17360908]
[42]
Harkany T, Penke B, Luiten PG. β-Amyloid excitotoxicity in rat magnocellular nucleus basalis. Effect of cortical deafferentation on cerebral blood flow regulation and implications for Alzheimer’s disease. Ann N Y Acad Sci 2000; 903: 374-86.
[http://dx.doi.org/10.1111/j.1749-6632.2000.tb06389.x] [PMID: 10818528]
[43]
Miguel-Hidalgo JJ, Alvarez XA, Cacabelos R, Quack G. Neuroprotection by memantine against neurodegeneration induced by beta-amyloid(1-40). Brain Res 2002; 958(1): 210-21.
[http://dx.doi.org/10.1016/S0006-8993(02)03731-9] [PMID: 12468047]
[44]
Texidó L, Martín-Satué M, Alberdi E, Solsona C, Matute C. Amyloid β peptide oligomers directly activate NMDA receptors. Cell Calcium 2011; 49(3): 184-90.
[http://dx.doi.org/10.1016/j.ceca.2011.02.001] [PMID: 21349580]
[45]
Ferreira IL, Bajouco LM, Mota SI, Auberson YP, Oliveira CR, Rego AC. Amyloid beta peptide 1-42 disturbs intracellular calcium homeostasis through activation of GluN2B-containing N-methyl-d-aspartate receptors in cortical cultures. Cell Calcium 2012; 51(2): 95-106.
[http://dx.doi.org/10.1016/j.ceca.2011.11.008] [PMID: 22177709]
[46]
Varga E, Juhász G, Bozsó Z, Penke B, Fülöp L, Szegedi V. Abeta(1-42) enhances neuronal excitability in the CA1 via NR2B subunit-containing NMDA receptors. Neural Plast 2014; 2014: 584314.
[http://dx.doi.org/10.1155/2014/584314] [PMID: 25276438]
[47]
Li S, Jin M, Koeglsperger T, Shepardson NE, Shankar GM, Selkoe DJ. Soluble Aβ oligomers inhibit long-term potentiation through a mechanism involving excessive activation of extrasynaptic NR2B-containing NMDA receptors. J Neurosci 2011; 31(18): 6627-38.
[http://dx.doi.org/10.1523/JNEUROSCI.0203-11.2011] [PMID: 21543591]
[48]
Chapman PF, White GL, Jones MW, et al. Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nat Neurosci 1999; 2(3): 271-6.
[http://dx.doi.org/10.1038/6374] [PMID: 10195221]
[49]
Palop JJ, Chin J, Roberson ED, et al. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer’s disease. Neuron 2007; 55(5): 697-711.
[http://dx.doi.org/10.1016/j.neuron.2007.07.025] [PMID: 17785178]
[50]
Lanté F, Chafai M, Raymond EF, et al. Subchronic glucocorticoid receptor inhibition rescues early episodic memory and synaptic plasticity deficits in a mouse model of Alzheimer’s disease. Neuropsychopharmacology 2015; 40(7): 1772-81.
[http://dx.doi.org/10.1038/npp.2015.25] [PMID: 25622751]
[51]
Trinchese F, Liu S, Battaglia F, Walter S, Mathews PM, Arancio O. Progressive age-related development of Alzheimer-like pathology in APP/PS1 mice. Ann Neurol 2004; 55(6): 801-14.
[http://dx.doi.org/10.1002/ana.20101] [PMID: 15174014]
[52]
Kimura R, Ohno M. Impairments in remote memory stabilization precede hippocampal synaptic and cognitive failures in 5XFAD Alzheimer mouse model. Neurobiol Dis 2009; 33(2): 229-35.
[http://dx.doi.org/10.1016/j.nbd.2008.10.006] [PMID: 19026746]
[53]
Latif-Hernandez A, Sabanov V, Ahmed T, et al. The two faces of synaptic failure in AppNL-G-F knock-in mice. Alzheimers Res Ther 2020; 12(1): 100.
[http://dx.doi.org/10.1186/s13195-020-00667-6] [PMID: 32838792]
[54]
Dick O, Bading H. Synaptic activity and nuclear calcium signaling protect hippocampal neurons from death signal-associated nuclear translocation of FoxO3a induced by extrasynaptic N-methyl-D-aspartate receptors. J Biol Chem 2010; 285(25): 19354-61.
[http://dx.doi.org/10.1074/jbc.M110.127654] [PMID: 20404335]
[55]
Xu J, Kurup P, Zhang Y, et al. Extrasynaptic NMDA receptors couple preferentially to excitotoxicity via calpain-mediated cleavage of STEP. J Neurosci 2009; 29(29): 9330-43.
[http://dx.doi.org/10.1523/JNEUROSCI.2212-09.2009] [PMID: 19625523]
[56]
Liu DD, Yang Q, Li ST. Activation of extrasynaptic NMDA receptors induces LTD in rat hippocampal CA1 neurons. Brain Res Bull 2013; 93: 10-6.
[http://dx.doi.org/10.1016/j.brainresbull.2012.12.003] [PMID: 23270879]
[57]
Papouin T, Ladépêche L, Ruel J, et al. Synaptic and extrasynaptic NMDA receptors are gated by different endogenous coagonists. Cell 2012; 150(3): 633-46.
[http://dx.doi.org/10.1016/j.cell.2012.06.029] [PMID: 22863013]
[58]
Hardingham GE, Bading H. Synaptic versus extrasynaptic NMDA receptor signalling: Implications for neurodegenerative disorders. Nat Rev Neurosci 2010; 11(10): 682-96.
[http://dx.doi.org/10.1038/nrn2911] [PMID: 20842175]
[59]
Hardingham GE, Fukunaga Y, Bading H. Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nat Neurosci 2002; 5(5): 405-14.
[http://dx.doi.org/10.1038/nn835] [PMID: 11953750]
[60]
Snyder EM, Nong Y, Almeida CG, et al. Regulation of NMDA receptor trafficking by amyloid-β. Nat Neurosci 2005; 8(8): 1051-8.
[http://dx.doi.org/10.1038/nn1503] [PMID: 16025111]
[61]
Dewachter I, Filipkowski RK, Priller C, et al. Deregulation of NMDA-receptor function and down-stream signaling in APP[V717I] transgenic mice. Neurobiol Aging 2009; 30(2): 241-56.
[http://dx.doi.org/10.1016/j.neurobiolaging.2007.06.011] [PMID: 17673336]
[62]
Matos M, Augusto E, Oliveira CR, Agostinho P. Amyloid-beta peptide decreases glutamate uptake in cultured astrocytes: Involvement of oxidative stress and mitogen-activated protein kinase cascades. Neuroscience 2008; 156(4): 898-910.
[http://dx.doi.org/10.1016/j.neuroscience.2008.08.022] [PMID: 18790019]
[63]
Talantova M, Sanz-Blasco S, Zhang X, et al. Aβ induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic loss. Proc Natl Acad Sci USA 2013; 110(27): E2518-27.
[http://dx.doi.org/10.1073/pnas.1306832110] [PMID: 23776240]
[64]
Zoia CP, Tagliabue E, Isella V, et al. Fibroblast glutamate transport in aging and in AD: Correlations with disease severity. Neurobiol Aging 2005; 26(6): 825-32.
[http://dx.doi.org/10.1016/j.neurobiolaging.2004.07.007] [PMID: 15718040]
[65]
Masliah E, Alford M, Mallory M, Rockenstein E, Moechars D, Van Leuven F. Abnormal glutamate transport function in mutant amyloid precursor protein transgenic mice. Exp Neurol 2000; 163(2): 381-7.
[http://dx.doi.org/10.1006/exnr.2000.7386] [PMID: 10833311]
[66]
Masliah E, Alford M, DeTeresa R, Mallory M, Hansen L. Deficient glutamate transport is associated with neurodegeneration in Alzheimer’s disease. Ann Neurol 1996; 40(5): 759-66.
[http://dx.doi.org/10.1002/ana.410400512] [PMID: 8957017]
[67]
Wu SZ, Bodles AM, Porter MM, Griffin WS, Basile AS, Barger SW. Induction of serine racemase expression and D-serine release from microglia by amyloid beta-peptide. J Neuroinflammation 2004; 1(1): 2.
[http://dx.doi.org/10.1186/1742-2094-1-2] [PMID: 15285800]
[68]
Madeira C, Lourenco MV, Vargas-Lopes C, et al. D-serine levels in Alzheimer’s disease: Implications for novel biomarker development. Transl Psychiatry 2015; 5(5): e561.
[http://dx.doi.org/10.1038/tp.2015.52] [PMID: 25942042]
[69]
Inoue R, Hashimoto K, Harai T, Mori H. NMDA- and β-amyloid1-42-induced neurotoxicity is attenuated in serine racemase knock-out mice. J Neurosci 2008; 28(53): 14486-91.
[http://dx.doi.org/10.1523/JNEUROSCI.5034-08.2008] [PMID: 19118183]
[70]
Liu H, Li S, Yang C, et al. D-Serine ameliorates motor and cognitive impairments in β-amyloid 1-42 injected mice by inhibiting JNK signaling pathway. J Chem Neuroanat 2020; 109: 101852.
[http://dx.doi.org/10.1016/j.jchemneu.2020.101852] [PMID: 32781134]
[71]
Fukuyama H, Ogawa M, Yamauchi H, et al. Altered cerebral energy metabolism in Alzheimer’s disease: A PET study. J Nucl Med 1994; 35(1): 1-6.
[PMID: 8271029]
[72]
An Y, Varma VR, Varma S, et al. Evidence for brain glucose dysregulation in Alzheimer’s disease. Alzheimers Dement 2018; 14(3): 318-29.
[http://dx.doi.org/10.1016/j.jalz.2017.09.011] [PMID: 29055815]
[73]
Le Douce J, Maugard M, Veran J, et al. Impairment of glycolysis-derived L-serine production in astrocytes contributes to cognitive deficits in Alzheimer’s disease. Cell Metab 2020; 31(3): 503-517.e8.
[http://dx.doi.org/10.1016/j.cmet.2020.02.004] [PMID: 32130882]
[74]
Lin CH, Chen PK, Wang SH, Lane HY. Sodium benzoate for the treatment of behavioral and psychological symptoms of dementia (BPSD): A randomized, double-blind, placebo-controlled, 6-week trial. J Psychopharmacol 2019; 33(8): 1030-3.
[http://dx.doi.org/10.1177/0269881119849815] [PMID: 31113277]
[75]
Piubelli L, Pollegioni L, Rabattoni V, et al. Serum D-serine levels are altered in early phases of Alzheimer’s disease: Towards a precocious biomarker. Transl Psychiatry 2021; 11(1): 77.
[http://dx.doi.org/10.1038/s41398-021-01202-3] [PMID: 33500383]
[76]
Chang CH, Kuo HL, Ma WF, Tsai HC. Cerebrospinal fluid and serum D-serine levels in patients with Alzheimer’s disease: A systematic review and meta-analysis. J Clin Med 2020; 9(12): E3840.
[http://dx.doi.org/10.3390/jcm9123840] [PMID: 33256147]
[77]
Hashimoto K, Fukushima T, Shimizu E, et al. Possible role of D-serine in the pathophysiology of Alzheimer’s disease. Prog Neuropsychopharmacol Biol Psychiatry 2004; 28(2): 385-8.
[http://dx.doi.org/10.1016/j.pnpbp.2003.11.009] [PMID: 14751437]
[78]
Nuzzo T, Miroballo M, Casamassa A, et al. Cerebrospinal fluid and serum D-serine concentrations are unaltered across the whole clinical spectrum of Alzheimer’s disease. Biochim Biophys Acta Proteins Proteomics 2020; 1868(12): 140537.
[http://dx.doi.org/10.1016/j.bbapap.2020.140537] [PMID: 32896673]
[79]
Biemans EA, Verhoeven-Duif NM, Gerrits J, Claassen JA, Kuiperij HB, Verbeek MM. CSF D-serine concentrations are similar in Alzheimer’s disease, other dementias, and elderly controls. Neurobiol Aging 2016; 42: 213-6.
[http://dx.doi.org/10.1016/j.neurobiolaging.2016.03.017] [PMID: 27143438]
[80]
Ploux E, Freret T, Billard JM. D-serine in physiological and pathological brain aging. Biochim Biophys Acta Proteins Proteomics 2021; 1869(1): 140542.
[http://dx.doi.org/10.1016/j.bbapap.2020.140542] [PMID: 32950692]
[81]
Li Z, Xing Y, Guo X, Cui Y. Development of an UPLC-MS/MS method for simultaneous quantitation of 11 d-amino acids in different regions of rat brain: Application to a study on the associations of D-amino acid concentration changes and Alzheimer’s disease. J Chromatogr B Analyt Technol Biomed Life Sci 2017; 1058: 40-6.
[http://dx.doi.org/10.1016/j.jchromb.2017.05.011] [PMID: 28531844]
[82]
Glass CK, Saijo K, Winner B, Marchetto MC, Gage FH. Mechanisms underlying inflammation in neurodegeneration. Cell 2010; 140(6): 918-34.
[http://dx.doi.org/10.1016/j.cell.2010.02.016] [PMID: 20303880]
[83]
Rogers J, Luber-Narod J, Styren SD, Civin WH. Expression of immune system-associated antigens by cells of the human central nervous system: Relationship to the pathology of Alzheimer’s disease. Neurobiol Aging 1988; 9(4): 339-49.
[http://dx.doi.org/10.1016/S0197-4580(88)80079-4] [PMID: 3263583]
[84]
Heneka MT, Carson MJ, El Khoury J, et al. Neuroinflammation in Alzheimer’s disease. Lancet Neurol 2015; 14(4): 388-405.
[http://dx.doi.org/10.1016/S1474-4422(15)70016-5] [PMID: 25792098]
[85]
Heneka MT, O’Banion MK. Inflammatory processes in Alzheimer’s disease. J Neuroimmunol 2007; 184(1-2): 69-91.
[http://dx.doi.org/10.1016/j.jneuroim.2006.11.017] [PMID: 17222916]
[86]
Yu Y, Ye RD. Microglial Aβ receptors in Alzheimer’s disease. Cell Mol Neurobiol 2015; 35(1): 71-83.
[http://dx.doi.org/10.1007/s10571-014-0101-6] [PMID: 25149075]
[87]
Liddelow SA, Guttenplan KA, Clarke LE, et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature 2017; 541(7638): 481-7.
[http://dx.doi.org/10.1038/nature21029] [PMID: 28099414]
[88]
Li S, Uno Y, Rudolph U, et al. Astrocytes in primary cultures express serine racemase, synthesize D-serine and acquire A1 reactive astrocyte features. Biochem Pharmacol 2018; 151: 245-51.
[http://dx.doi.org/10.1016/j.bcp.2017.12.023] [PMID: 29305854]
[89]
Wang Y, Hancock AM, Bradner J, et al. Complement 3 and factor h in human cerebrospinal fluid in Parkinson’s disease, Alzheimer’s disease, and multiple-system atrophy. Am J Pathol 2011; 178(4): 1509-16.
[http://dx.doi.org/10.1016/j.ajpath.2011.01.006] [PMID: 21435440]
[90]
Hikida T, Mustafa AK, Maeda K, et al. Modulation of D-serine levels in brains of mice lacking PICK1. Biol Psychiatry 2008; 63(10): 997-1000.
[http://dx.doi.org/10.1016/j.biopsych.2007.09.025] [PMID: 18191108]
[91]
Kim PM, Aizawa H, Kim PS, et al. Serine racemase: Activation by glutamate neurotransmission via glutamate receptor interacting protein and mediation of neuronal migration. Proc Natl Acad Sci USA 2005; 102(6): 2105-10.
[http://dx.doi.org/10.1073/pnas.0409723102] [PMID: 15684087]
[92]
Ma TM, Paul BD, Fu C, et al. Serine racemase regulated by binding to stargazin and PSD-95: Potential N-methyl-D-aspartate-α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (NMDA-AMPA) glutamate neurotransmission cross-talk. J Biol Chem 2014; 289(43): 29631-41.
[http://dx.doi.org/10.1074/jbc.M114.571604] [PMID: 25164819]
[93]
Balan L, Foltyn VN, Zehl M, et al. Feedback inactivation of D-serine synthesis by NMDA receptor-elicited translocation of serine racemase to the membrane. Proc Natl Acad Sci USA 2009; 106(18): 7589-94.
[http://dx.doi.org/10.1073/pnas.0809442106] [PMID: 19380732]
[94]
Kolodney G, Dumin E, Safory H, et al. Nuclear compartmentalization of serine racemase regulates D-serine production: Implications for N-methyl-D-aspartate (NMDA) receptor activation. J Biol Chem 2015; 290(52): 31037-50.
[http://dx.doi.org/10.1074/jbc.M115.699496] [PMID: 26553873]
[95]
Cuomo M, Keller S, Punzo D, et al. Selective demethylation of two CpG sites causes postnatal activation of the Dao gene and consequent removal of D-serine within the mouse cerebellum. Clin Epigenetics 2019; 11(1): 149.
[http://dx.doi.org/10.1186/s13148-019-0732-z] [PMID: 31661019]
[96]
Zhang H, Kuang XL, Chang Y, Lu J, Jiang H, Wu S. Reduced serine racemase expression in aging rat cerebellum is associated with oxidative DNA stress and hypermethylation in the promoter. Brain Res 2015; 1629: 221-30.
[http://dx.doi.org/10.1016/j.brainres.2015.10.034] [PMID: 26505919]
[97]
Furuya S, Watanabe M. Novel neuroglial and glioglial relationships mediated by L-serine metabolism. Arch Histol Cytol 2003; 66(2): 109-21.
[http://dx.doi.org/10.1679/aohc.66.109] [PMID: 12846552]
[98]
Yang JH, Wada A, Yoshida K, et al. Brain-specific Phgdh deletion reveals a pivotal role for L-serine biosynthesis in controlling the level of D-serine, an N-methyl-D-aspartate receptor co-agonist, in adult brain. J Biol Chem 2010; 285(53): 41380-90.
[http://dx.doi.org/10.1074/jbc.M110.187443] [PMID: 20966073]
[99]
Wu S, Barger SW. Induction of serine racemase by inflammatory stimuli is dependent on AP-1. Ann N Y Acad Sci 2004; 1035(1): 133-46.
[http://dx.doi.org/10.1196/annals.1332.009] [PMID: 15681805]
[100]
Berson A, Nativio R, Berger SL, Bonini NM. Epigenetic regulation in neurodegenerative diseases. Trends Neurosci 2018; 41(9): 587-98.
[http://dx.doi.org/10.1016/j.tins.2018.05.005] [PMID: 29885742]
[101]
Chouliaras L, Rutten BP, Kenis G, et al. Epigenetic regulation in the pathophysiology of Alzheimer’s disease. Prog Neurobiol 2010; 90(4): 498-510.
[http://dx.doi.org/10.1016/j.pneurobio.2010.01.002] [PMID: 20097254]

Rights & Permissions Print Cite
Article Metrics
62
3
Wayfinder Image
© 2024 Bentham Science Publishers | Privacy Policy